BRPI1005293A2 - composição e método para aumentar a solubilidade de uma droga lipofílica e respectivo método de tratamento - Google Patents

composição e método para aumentar a solubilidade de uma droga lipofílica e respectivo método de tratamento

Info

Publication number
BRPI1005293A2
BRPI1005293A2 BRPI1005293A BRPI1005293A BRPI1005293A2 BR PI1005293 A2 BRPI1005293 A2 BR PI1005293A2 BR PI1005293 A BRPI1005293 A BR PI1005293A BR PI1005293 A BRPI1005293 A BR PI1005293A BR PI1005293 A2 BRPI1005293 A2 BR PI1005293A2
Authority
BR
Brazil
Prior art keywords
solubility
increasing
treatment
composition
lipophilic drug
Prior art date
Application number
BRPI1005293A
Other languages
English (en)
Inventor
Brian Charles Keller
Original Assignee
Brian Charles Keller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brian Charles Keller filed Critical Brian Charles Keller
Publication of BRPI1005293A2 publication Critical patent/BRPI1005293A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
BRPI1005293A 2009-01-23 2010-01-22 composição e método para aumentar a solubilidade de uma droga lipofílica e respectivo método de tratamento BRPI1005293A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20584009P 2009-01-23 2009-01-23
PCT/US2010/000165 WO2010085347A1 (en) 2009-01-23 2010-01-22 Peg-lipid conjugates for icreasing the solubility of drug compounds

Publications (1)

Publication Number Publication Date
BRPI1005293A2 true BRPI1005293A2 (pt) 2019-09-24

Family

ID=42356156

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1005293A BRPI1005293A2 (pt) 2009-01-23 2010-01-22 composição e método para aumentar a solubilidade de uma droga lipofílica e respectivo método de tratamento

Country Status (6)

Country Link
US (1) US20100210518A1 (pt)
EP (1) EP2389156A1 (pt)
JP (1) JP2012515774A (pt)
BR (1) BRPI1005293A2 (pt)
CO (1) CO6410280A2 (pt)
WO (1) WO2010085347A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8127185B2 (en) 2009-01-23 2012-02-28 Micron Technology, Inc. Memory devices and methods for managing error regions
WO2011139343A2 (en) * 2010-04-28 2011-11-10 Wu Nian Amino acid linked peg-lipid conjugates
US20120202890A1 (en) * 2011-02-08 2012-08-09 Nian Wu Polymer-carbohydrate-lipid conjugates
US20120219598A1 (en) * 2011-02-22 2012-08-30 Uhrich Kathryn E Polymeric micelles for reducing ldl in vivo
US8883177B2 (en) 2011-06-28 2014-11-11 Nian Wu Pharmaceutical compositions for parenteral administration
US10064954B2 (en) 2015-06-23 2018-09-04 Nian Wu Polymer-cyclodextrin-lipid conjugates
AU2023329397A1 (en) * 2022-08-26 2025-03-06 Renagade Therapeutics Management Inc. Pegylated lipid compounds and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US7794595B2 (en) * 2006-08-28 2010-09-14 Brian Charles Keller Method for encapsulation, remediation and recovery of spilled oil

Also Published As

Publication number Publication date
WO2010085347A1 (en) 2010-07-29
EP2389156A1 (en) 2011-11-30
CO6410280A2 (es) 2012-03-30
JP2012515774A (ja) 2012-07-12
US20100210518A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
IL260582B (en) Derivatives of oxyntomodulin and a pharmaceutical preparation containing them for the treatment of obesity
BR112012002102A2 (pt) composição farmaceutica e metodo para preparar uma composição farmaceutica
PL3181134T3 (pl) Bifidobakterie do leczenia cukrzycy i stanów pokrewnych
BRPI0923895A2 (pt) Cápsula para o preparo de uma bebida e dispositivo
PT2504005E (pt) Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
BRPI0815387A2 (pt) composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI0909750A2 (pt) dispositivo e cápsula para a preparação de uma bebida
EP2395941A4 (en) MULTILAYER SURGICAL PROSTHESIS
BRPI1008598A2 (pt) composição farmacêutica para inalação
ZA201200239B (en) Derivative of glp-1 analogue or its pharmaceutical salts and their use
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BRPI1006229A2 (pt) composição incluindo uma quantidade suficiente de curcumina
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
BRPI1007484A2 (pt) composição farmacêutica para administração oral
BRPI1010086A2 (pt) método e produtos para tratamento de doenças
EP2213303A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
BRPI0917562A2 (pt) composições farmacêuticas e métodos para estabilizar as mesmas
BRPI0912890A2 (pt) composição farmacêutica para o tratamento de ejaculação precoce
EP2465512A4 (en) PAIN-SUBJECTIVE PHARMACEUTICAL COMPOSITION
ZA201108458B (en) Nitrile derivatives and their pharmaceutical use and compositions

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.